BioWorld Asia

April 11, 2007

Affimed Raises $33.5M For TandAbs In Oncology

Affimed Therapeutics AG raised €25 million (US$33.5 million) in a Series B round to fund its two lead programs, in non-Hodgkins lymphoma (NHL) and Hodgkin's disease. Each is in preclinical development at present. (BioWorld International) Read More

Stem Cells Sciences Raises $9.9M With New ASX Listing

Innate Immunity, New Combo Of Antibiotics Fight Resistance

Patients' Group Voices Anger At Advanced Therapies Tactic

Atlantic Closes First Deal, Licensing GI Compound

Nokad Obtains Its First Functional KOs in Rats

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 11, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...